Poolbeg Pharma PLC Poolbeg Partners with a Nasdaq-Listed Biopharma (2985Q)
17 Octubre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 2985Q
Poolbeg Pharma PLC
17 October 2023
Poolbeg Pharma plc
Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company
on its Oral Delivery Platform
Strategic collaboration focussed on the development of an
optimised drug for a metabolic condition using Poolbeg's licensed
oral delivery technology
Collaboration may expand to a full licensing agreement
17 October 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company targeting diseases with a high unmet medical need,
announces that it has signed a strategic collaboration agreement
with a Nasdaq listed biopharma company for the development of an
optimised oral drug to treat a metabolic condition.
Under the agreement, the Company will receive funding to work
with its new partner to produce a prototype drug utilising
Poolbeg's licensed oral delivery technology*. Poolbeg believes that
this technology can help to optimise the delivery of its partner's
novel drug to its ideal site of therapeutic action.
The Company is optimistic that this strategic collaboration can
progress to a full licensing agreement in time, whereby the Nasdaq
listed biopharma could integrate this novel oral delivery
technology into its pipeline.
This marks another significant milestone in Poolbeg's journey
towards early revenues and underscores the Company's commitment to
advancing treatments for metabolic conditions.
* Poolbeg has an exclusive licence to patented oral delivery
technologies for all metabolic conditions and is utilising the same
technology for its Oral GLP-1 agonist programme.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, said: "Our partner recognises the benefits of Poolbeg's
licensed oral delivery technology and we look forward to optimising
the development of this innovative drug for patients in an area
where there is a clear unmet need. We are optimistic that this
strategic collaboration has the potential to progress to a full
licensing agreement."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and utilising its licensed Oral Delivery Platform to
target metabolic conditions.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBIBDGGSBDGXL
(END) Dow Jones Newswires
October 17, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024